SEC Form 4 · accession 0001209191-17-049710
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wing Tak Wendy YU
Director
Period of report
Aug 18, 2017
Accepted (ET)
Aug 21, 2017 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.28 | Aug 18, 2017 | A | 40,000 | A | — | Aug 17, 2027 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The option vests in three equal annual installments beginning on August 18, 2018.